Medreich Limited

Medreich Limited, established on August 16, 1973, in Bengaluru, Karnataka, India, is a fully integrated pharmaceutical company specializing in contract manufacturing and development of pharmaceutical preparations across various dosage forms. The company operates under the Corporate Identification Number (CIN) U24232KA1973PLC002383. Medreich's authorized capital stands at ₹160.50 crore, with a paid-up capital of ₹40.16 crore.

In 2015, Medreich became a subsidiary of the Meiji Group, a leading Japanese conglomerate listed on the Tokyo Stock Exchange, with business interests spanning pharmaceuticals, food, and nutrition products. The company employs approximately 3,000 individuals worldwide, providing a robust platform for employee growth and development.

Medreich operates multiple state-of-the-art manufacturing facilities in India, including six in Bengaluru and one in Hyderabad. These facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC. The manufacturing units are equipped to produce a range of dosage forms, such as tablets, capsules, dry powders for suspensions, and dry powder for injections, adhering to stringent GMP standards.

As of July 31, 2023, Tsutomu Yamada serves as a Director at Medreich Limited. Pankaj Garg has been the Managing Director since July 31, 2015. Yasuhiro Nakagiri joined as an Additional Director on May 9, 2024. The leadership team is committed to driving the company's vision of global expansion through strong local partnerships.

Medreich has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals from regulatory bodies such as the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC. These approvals enable Medreich to supply pharmaceutical products to over 55 countries, including key markets in Europe, Australia, New Zealand, Canada, Japan, Far East Asia, GCC, Africa, Latin America, and the CIS.

Medreich has expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are approved by regulatory authorities in these regions, including South Africa's MCC and various Latin American countries. Additionally, Medreich has established subsidiaries in the United Kingdom and Australia, further enhancing its presence in these emerging markets.

Medreich's geographic strategy focuses on diversification across multiple regions, including Europe, Australia, New Zealand, Canada, Japan, Far East Asia, GCC, Africa, Latin America, and the CIS. This approach mitigates concentration risk and aligns with the company's vision of global expansion through strong local partnerships. The strategic direction emphasizes the development of patent non-infringing and niche generics in differentiated dosage forms for global regulated markets.

Medreich's manufacturing facilities are approved by the US FDA, enabling the company to supply pharmaceutical products to the United States market. The company has a track record of obtaining market authorizations in various regions, including the US, UK, Europe, Australia, New Zealand, Canada, Far East Asia, Latin America, and Africa. This regulatory compliance underscores Medreich's commitment to maintaining high-quality manufacturing standards.

Medreich's manufacturing facilities comply with WHO-GMP standards, ensuring the production of high-quality pharmaceutical products. The company's facilities are also approved by the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, reflecting adherence to international GMP standards. These certifications facilitate access to global markets and reinforce Medreich's commitment to quality.

Medreich holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India, ensuring compliance with national regulatory standards. The company's facilities are approved by various state drug controllers, and it possesses export No Objection Certificates (NOCs) for international shipments. These regulatory approvals demonstrate Medreich's adherence to both domestic and international standards.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Medreich Limited. The company's manufacturing facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, indicating a strong compliance record.

Medreich operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. The company's product portfolio includes antibiotics, cardiovascular drugs, and analgesics, with top products such as Flucloxacillin, Amoxicillin, and Rosuvastatin. Medreich's manufacturing facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, enabling the company to supply products to over 55 countries. This extensive regulatory compliance and global reach position Medreich as a significant player in the pharmaceutical manufacturing industry.

Medreich's key differentiators include its fully integrated operations, advanced research and development capabilities, and a strong focus on regulatory compliance. The company's manufacturing facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, ensuring adherence to international standards. Additionally, Medreich's strategic partnerships with multinational companies and its presence in over 55 countries underscore its competitive advantages in the pharmaceutical manufacturing sector.

Medreich's current strategic direction focuses on contract manufacturing and development of branded generics, with an emphasis on patent non-infringing and niche generics in differentiated dosage forms for global regulated markets. The company's manufacturing facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, facilitating access to international markets. Looking ahead, Medreich aims to expand its global footprint through strategic partnerships and continued investment in research and development.

Medreich has a strong track record in pharmaceutical manufacturing, with a total export value of $224.8 million USD and 7,285 shipments across 42 products in 15 therapeutic categories. The company's top five products—Flucloxacillin, Amoxicillin, Potassium, Rosuvastatin, and Atorvastatin—account for 51.9% of its portfolio, indicating a focused product strategy. Medreich's manufacturing facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, ensuring compliance with international standards. These factors contribute to Medreich's reliability as a supplier in the pharmaceutical industry.

Importers should verify the following certifications when sourcing from Medreich Limited:

• FDA Approval: Confirm that Medreich's manufacturing facilities are registered with the US FDA. This can be verified through the FDA's Establishment Registration & Device Listing database.

• WHO-GMP Certification: Ensure that Medreich's facilities comply with WHO-GMP standards. Verification can be done by reviewing the WHO's list of prequalified manufacturers.

• EU GMP Certification: Check that Medreich holds EU GMP certificates. This information is typically available through the European Medicines Agency (EMA) or the relevant national regulatory authority.

• ISO Certification: Verify that Medreich holds ISO certifications relevant to pharmaceutical manufacturing. These can be confirmed through the International Organization